Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this drugmaker would post earnings of $0.18 per share when it actually produced a loss of $0.02, delivering a surprise of -111.11%. Over the last four quarters, the company has ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Second Quarter 2024 Results – LINZESS(Iinaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – B ...

Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 2 cents per share for first-quarter 2024 in contrast to the Zacks Consensus Estimate of earnings of 18 cents per share. The company had recorded adjusted earnings of 25 cents per share in the year-ago quarter.Total revenues in the reported quarter were $74.9 million, which significantly missed the Zacks Consensus Estimate of $103 million. The top line decreased almost 28% year over year due to a $30.0 million gross-to-net change in estimate ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET I would now like to turn the call over to Matt Roache, Director of Investor Relations. Please go ahead. A discussion of these statements and risk factors is available on the current safe harbor statement slide, as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2023, and in our subsequent SEC filings. All forward-looking statements speak as of the date ...

16 20 month Long-Term Safety and Durability 42 patients with PBC Randomized, Double-blinded, placebo-controlled, parallel assignment Doses: Placebo, CNP-104 4mg/kg, CNP-104 8mg/kg IV Infusion on Days 1 and 8 10 | --- | --- | --- | |--------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Sravan Emany Commercial Update, Q1 2024 Financial Highlights and Revised FY 2024 Guidance | | | | | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other j ...

Exhibit 99.1 Ironwood Pharmaceuticals Reports First Quarter 2024 Results – Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus- Host Disease (SR GI aGVHD) – – LINZESS (Iinaclotide) EUTRx prescription demand growth of 10% year-over-year – – Re ...

Investing in the biotech sphere isn’t for the faint of heart, and you should steer clear of the biotech stocks to avoid. That’s because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals. Unsurprisingly, the SPDR S&P Biotech ETF had shed roughly 40% in value over the past three years, when the broader market gained 22%. Hence, investors pondering over biotech stocks to avoid them will always remain relevant.  Moreover, they’re probably even more ...

Table of Contents IRONWOOD PHARMACEUTICALS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34620 (Exact name of registrant as specified in its charter) Delaware (State or othe ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript February 15, 2024 8:30 AM ET Company Participants | --- | |--------------------------------------------------------| | | | Matt Roache - Director of Investor Relations | | Tom McCourt - Chief Executive Officer | | Mike Shetzline - Chief Medical Officer | | Sravan Emany - Chief Financial Officer | | Conference Call Participants | | Amy Li - Jefferies | | | | Mohit Bansal - Wells Fargo | | Chase Knickerbocker - Craig-Hallum | | Jaso ...